SIREN : 489736702
SPFPL PHARMA 52. is a French company founded 20 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in FOULAIN (52000), this company of category PME shows in 2019 a revenue of 922 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2019 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | N/C | N/C | 922 272 € | 1 502 927 € | 1 546 297 € |
| Net income | 141 328 € | -6 169 € | 84 596 € | 92 579 € | 83 641 € | 82 861 € | -46 112 € | -96 909 € | 93 743 € | 105 325 € |
| EBITDA | -3 206 € | -1 881 € | -2 075 € | -1 472 € | -1 946 € | -5 083 € | -44 839 € | 74 431 € | 127 600 € | 130 657 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | N/C | N/C | -10.5% | 6.2% | 6.8% |
In 2025, SPFPL PHARMA 52. generates positive net income of 141 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 105 k€ -> 141 k€.
-3 206 €
-3 206 €
141 328 €
The debt ratio (= Financial debt / Equity x 100) stands at 49%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 67%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.4 years of cash flow to repay all financial debt. This ratio remains within usual banking standards.
49.305%
66.924%
3.365
In 2025, the debt ratio of SPFPL PHARMA 52. (49.30) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of SPFPL PHARMA 52. (66.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2025, the repayment capacity of SPFPL PHARMA 52. (3.37) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 23433.45. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
23433.451
-142.14
In 2025, the liquidity ratio of SPFPL PHARMA 52. (23433.45) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2025, the interest coverage of SPFPL PHARMA 52. (-142.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 76 days. Excellent situation: suppliers finance 76 days of the operating cycle (retail model).
0 €
0 j
76 j
0 j
Based on 170 transactions of similar company sales (all years), the value of SPFPL PHARMA 52. is estimated at 1 465 119 € (range 908 160€ - 2 278 721€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SPFPL PHARMA 52. with other companies in the same sector:
Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires
The revenue of SPFPL PHARMA 52. in 2019 is 922 k€.
Yes, SPFPL PHARMA 52. generated a net profit of 141 k€ in 2025.
The headquarters of SPFPL PHARMA 52. is located in FOULAIN (52000), in the department Haute-Marne.
The tax return of SPFPL PHARMA 52. is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPFPL PHARMA 52. operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.